Graphene-based hybrid nanoparticle of doxorubicin for cancer chemotherapy

Nagaraja SreeHarsha,1 Rahul Maheshwari,2,3 Bandar E Al-Dhubiab,1 Muktika Tekade,4 Mukesh Chandra Sharma,4 Katharigatta N Venugopala,1,5 Rakesh Kumar Tekade,2,6–7 Abdullah M Alzahrani8 1Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Sau...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	SreeHarsha N, Maheshwari R, Al-Dhubiab BE, Tekade M, Sharma MC, Venugopala KN, Tekade RK, Alzahrani AM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Graphene Photothermal Chitosan Hybrid nanoparticles (HNP) Prostate Cancer Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/badcd54a433d43b383de603d6db85f7c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:badcd54a433d43b383de603d6db85f7c
record_format	dspace
spelling	oai:doaj.org-article:badcd54a433d43b383de603d6db85f7c2021-12-02T05:43:57ZGraphene-based hybrid nanoparticle of doxorubicin for cancer chemotherapy1178-2013https://doaj.org/article/badcd54a433d43b383de603d6db85f7c2019-09-01T00:00:00Zhttps://www.dovepress.com/graphene-based-hybrid-nanoparticle-of-doxorubicin-for-cancer-chemother-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Nagaraja SreeHarsha,1 Rahul Maheshwari,2,3 Bandar E Al-Dhubiab,1 Muktika Tekade,4 Mukesh Chandra Sharma,4 Katharigatta N Venugopala,1,5 Rakesh Kumar Tekade,2,6–7 Abdullah M Alzahrani8 1Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia; 2National Institute of Pharmaceutical Education and Research (NIPER) – Ahmedabad, Gandhinagar, Gujarat 382355, India; 3School of Pharmacy and Technology Management, SVKM’s NMIMS, Hyderabad Campus, Hyderabad, Telangana 509 301, India; 4School of Pharmacy, Devi Ahilya Vishwavidyalaya, Takshila Campus, Indore, MP 452001, India; 5Department of Biotechnology and Food Technology, Durban University of Technology, Durban 4001, South Africa; 6Department of Pharmaceutical Technology, The International Medical University, School of Pharmacy, Kuala Lumpur 57000, Malaysia; 7Department of Materials Engineering, Indian Institute of Technology-Jammu, Jammu - 181 221, J&K, India; 8Department of Biological Sciences, College of Science, King Faisal University, Al-Ahsa, Saudi ArabiaCorrespondence: Nagaraja SreeHarshaDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, PO Box 380, Al-Ahsa 31982, Saudi ArabiaEmail sharsha@kfu.edu.saBackground: Prostate cancer (PC) has the highest prevalence in men and accounts for a high rate of neoplasia-related death. Doxorubicin (DOX) is one of the most widely used anti-neoplastic drugs for prostate cancer among others. However, it has low specificity and many side effects and affects normal cells. More recently, there have been newly developed drug delivery tools which are graphene or graphene-based, used to increase the specificity of the delivered drug molecules. The graphene derivatives possess both π-π stacking and increased hydrophobicity, factors that increase the likelihood of drug delivery. Despite this, the hydrophilicity of graphene remains problematic, as it induced problems with stability. For this reason, the use of a chitosan coating remains one way to modify the surface features of graphene.Method: In this investigation, a hybrid nanoparticle that consisted of a DOX-loaded reduced graphene oxide that is stabilized with chitosan (rGOD-HNP) was developed.Result: The newly developed rGOD-HNP demonstrated high biocompatibility and efficiency in entrapping DOX (&sim;65%) and releasing it in a controlled manner (&sim;50% release in 48 h). Furthermore, it was also demonstrated that rGOD-HNP can intracellularly deliver DOX and more specifically in PC-3 prostate cancer cells.Conclusion: This delivery tool offers a feasible and viable method to deliver DOX photo-thermally in the treatment of prostate cancer.Keywords: graphene, photothermal, chitosan, hybrid nanoparticles, HNP, prostate cancerSreeHarsha NMaheshwari RAl-Dhubiab BETekade MSharma MCVenugopala KNTekade RKAlzahrani AMDove Medical PressarticleGraphenePhotothermalChitosanHybrid nanoparticles (HNP)Prostate CancerMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 7419-7429 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Graphene Photothermal Chitosan Hybrid nanoparticles (HNP) Prostate Cancer Medicine (General) R5-920
spellingShingle	Graphene Photothermal Chitosan Hybrid nanoparticles (HNP) Prostate Cancer Medicine (General) R5-920 SreeHarsha N Maheshwari R Al-Dhubiab BE Tekade M Sharma MC Venugopala KN Tekade RK Alzahrani AM Graphene-based hybrid nanoparticle of doxorubicin for cancer chemotherapy
description	Nagaraja SreeHarsha,1 Rahul Maheshwari,2,3 Bandar E Al-Dhubiab,1 Muktika Tekade,4 Mukesh Chandra Sharma,4 Katharigatta N Venugopala,1,5 Rakesh Kumar Tekade,2,6–7 Abdullah M Alzahrani8 1Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia; 2National Institute of Pharmaceutical Education and Research (NIPER) – Ahmedabad, Gandhinagar, Gujarat 382355, India; 3School of Pharmacy and Technology Management, SVKM’s NMIMS, Hyderabad Campus, Hyderabad, Telangana 509 301, India; 4School of Pharmacy, Devi Ahilya Vishwavidyalaya, Takshila Campus, Indore, MP 452001, India; 5Department of Biotechnology and Food Technology, Durban University of Technology, Durban 4001, South Africa; 6Department of Pharmaceutical Technology, The International Medical University, School of Pharmacy, Kuala Lumpur 57000, Malaysia; 7Department of Materials Engineering, Indian Institute of Technology-Jammu, Jammu - 181 221, J&K, India; 8Department of Biological Sciences, College of Science, King Faisal University, Al-Ahsa, Saudi ArabiaCorrespondence: Nagaraja SreeHarshaDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, PO Box 380, Al-Ahsa 31982, Saudi ArabiaEmail sharsha@kfu.edu.saBackground: Prostate cancer (PC) has the highest prevalence in men and accounts for a high rate of neoplasia-related death. Doxorubicin (DOX) is one of the most widely used anti-neoplastic drugs for prostate cancer among others. However, it has low specificity and many side effects and affects normal cells. More recently, there have been newly developed drug delivery tools which are graphene or graphene-based, used to increase the specificity of the delivered drug molecules. The graphene derivatives possess both π-π stacking and increased hydrophobicity, factors that increase the likelihood of drug delivery. Despite this, the hydrophilicity of graphene remains problematic, as it induced problems with stability. For this reason, the use of a chitosan coating remains one way to modify the surface features of graphene.Method: In this investigation, a hybrid nanoparticle that consisted of a DOX-loaded reduced graphene oxide that is stabilized with chitosan (rGOD-HNP) was developed.Result: The newly developed rGOD-HNP demonstrated high biocompatibility and efficiency in entrapping DOX (&sim;65%) and releasing it in a controlled manner (&sim;50% release in 48 h). Furthermore, it was also demonstrated that rGOD-HNP can intracellularly deliver DOX and more specifically in PC-3 prostate cancer cells.Conclusion: This delivery tool offers a feasible and viable method to deliver DOX photo-thermally in the treatment of prostate cancer.Keywords: graphene, photothermal, chitosan, hybrid nanoparticles, HNP, prostate cancer
format	article
author	SreeHarsha N Maheshwari R Al-Dhubiab BE Tekade M Sharma MC Venugopala KN Tekade RK Alzahrani AM
author_facet	SreeHarsha N Maheshwari R Al-Dhubiab BE Tekade M Sharma MC Venugopala KN Tekade RK Alzahrani AM
author_sort	SreeHarsha N
title	Graphene-based hybrid nanoparticle of doxorubicin for cancer chemotherapy
title_short	Graphene-based hybrid nanoparticle of doxorubicin for cancer chemotherapy
title_full	Graphene-based hybrid nanoparticle of doxorubicin for cancer chemotherapy
title_fullStr	Graphene-based hybrid nanoparticle of doxorubicin for cancer chemotherapy
title_full_unstemmed	Graphene-based hybrid nanoparticle of doxorubicin for cancer chemotherapy
title_sort	graphene-based hybrid nanoparticle of doxorubicin for cancer chemotherapy
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/badcd54a433d43b383de603d6db85f7c
work_keys_str_mv	AT sreeharshan graphenebasedhybridnanoparticleofdoxorubicinforcancerchemotherapy AT maheshwarir graphenebasedhybridnanoparticleofdoxorubicinforcancerchemotherapy AT aldhubiabbe graphenebasedhybridnanoparticleofdoxorubicinforcancerchemotherapy AT tekadem graphenebasedhybridnanoparticleofdoxorubicinforcancerchemotherapy AT sharmamc graphenebasedhybridnanoparticleofdoxorubicinforcancerchemotherapy AT venugopalakn graphenebasedhybridnanoparticleofdoxorubicinforcancerchemotherapy AT tekaderk graphenebasedhybridnanoparticleofdoxorubicinforcancerchemotherapy AT alzahraniam graphenebasedhybridnanoparticleofdoxorubicinforcancerchemotherapy
_version_	1718400253582901248

Graphene-based hybrid nanoparticle of doxorubicin for cancer chemotherapy

Ejemplares similares